Streetbeat News

Products Services

BMY

Bristol Myers Squibb announced positive long-term results from the Phase 3 DAYBREAK trial for Zeposia in treating relapsing forms of Multiple Sclerosis, highlighting its efficacy and safety profile.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 12:00 pm

TARS

Tarsus Pharmaceuticals (NASDAQ:TARS) has been analyzed by 4 analysts, showing a shift towards a more cautious stance in the last 30 days with ratings ranging from bullish to indifferent. The average 12-month price target for TARS has been raised to $49.00, indicating a 19.51% increase from the previous target. The company, focusing on ophthalmic conditions treatment, has shown significant revenue growth but struggles with profitability and efficiency metrics.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 12:00 pm

ANIP

ANI Pharmaceuticals projects its 2024 revenues from Purified Cortrophin Gel to be between $170M and $180M, marking an increase of 52% to 61%.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 11:56 am

STN

Stantec has been chosen to design Agratas, Tata Group's £4B battery manufacturing facility in the UK, expected to create up to 4,000 jobs and support thousands more in the supply chain.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 11:49 am

BTCUSD

Cryptocurrency analyst Willy Woo expressed optimism about Bitcoin's future, attributing it to increased institutional interest following the approval of spot Bitcoin ETFs. Woo's banker, with 33 years in wealth management, changed his stance to bullish on Bitcoin after the ETF approval, highlighting its recommendation for all investors. Since the introduction of spot Bitcoin ETFs, Bitcoin's price surged by 34.62%, trading at $62,423.10. The approval of Bitcoin ETFs is seen as a significant development, with predictions of $150 billion inflows into spot Bitcoin ETFs by 2025.

Portfolio Pulse from Benzinga Neuro

February 29, 2024 | 11:48 am

ADBE

Adobe Inc. (NASDAQ:ADBE) has unveiled Project Music GenAI Control, an AI tool enabling users to create and edit custom music from text prompts. Developed in collaboration with the University of California, San Diego, and Carnegie Mellon University, this tool represents Adobe's continued expansion into generative AI, following the launch of Firefly. BMO Capital Markets analyst Keith Bachman has reiterated an Outperform rating on Adobe, with a price target of $645, highlighting the growth potential of generative AI for Adobe.

Portfolio Pulse from Rounak Jain

February 29, 2024 | 11:47 am

NFE

New Fortress Energy (NFE) has announced the operational status of its Barcarena LNG Terminal in Pará, Brazil. The terminal, with a capacity of 6 MTPA (300 TBtu), features the Energos Celsius Floating Storage Regasification Unit.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 11:40 am

ENVB

Enveric Biosciences (NASDAQ:ENVB) has signed three non-binding term sheets with an undisclosed biotech company for the out-licensing of three classes of compounds from its drug portfolio for mental health treatments. These agreements include exclusive, royalty-bearing global licenses, cash buyout options, and future rights to related assets. The compounds, part of Enveric's over 1,000 novel molecules, are aimed at treating depression, anxiety, and addiction disorders. The potential licensing deals could bring Enveric up to $200 million in milestone payments and fees, plus royalties ranging from 2.5% to 10% on future sales.

Portfolio Pulse from Lara Goldstein

February 29, 2024 | 11:35 am

NXU

Nxu, Inc. has signed an LOI with Electric Outdoors to integrate Nxu's EV charging technology into EO's portable solar generation units, aiming to enhance the EV camping experience.

Portfolio Pulse from Charles Gross

February 29, 2024 | 11:32 am

IMUX

Immunic announced the presentation of data from its Phase 2 CALLIPER and CALVID-1 trials of Vidofludimus Calcium (IMU-838) at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024. The trials focus on the effectiveness of IMU-838 in treating multiple sclerosis.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 11:32 am